These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

689 related articles for article (PubMed ID: 29211704)

  • 21. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.
    Lu YS; Kashida Y; Kulp SK; Wang YC; Wang D; Hung JH; Tang M; Lin ZZ; Chen TJ; Cheng AL; Chen CS
    Hepatology; 2007 Oct; 46(4):1119-30. PubMed ID: 17654699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Shikonin induces apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1 signaling antagonized by p300.
    Jeung YJ; Kim HG; Ahn J; Lee HJ; Lee SB; Won M; Jung CR; Im JY; Kim BK; Park SK; Son MJ; Chung KS
    Biochim Biophys Acta; 2016 Nov; 1863(11):2584-2593. PubMed ID: 27452907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.
    Jeon HS; Ahn MY; Park JH; Kim TH; Chun P; Kim WH; Kim J; Moon HR; Jung JH; Kim HS
    Int J Oncol; 2010 Aug; 37(2):419-28. PubMed ID: 20596669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
    Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
    Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells.
    Moku G; Vangala S; Yakati V; Gali CC; Saha S; Madamsetty VS; Vyas A
    Anticancer Agents Med Chem; 2022; 22(5):914-925. PubMed ID: 34488592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylase inhibitor (HDACi) upregulates activin A and activates the Smad signaling pathway in melanomas.
    Lee J; Ko J; Yi JY
    J Dermatol Sci; 2018 Apr; 90(1):13-20. PubMed ID: 29290529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting MTA1/HIF-1α signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression.
    Butt NA; Kumar A; Dhar S; Rimando AM; Akhtar I; Hancock JC; Lage JM; Pound CR; Lewin JR; Gomez CR; Levenson AS
    Cancer Med; 2017 Nov; 6(11):2673-2685. PubMed ID: 29024573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
    Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
    Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells.
    Xu XD; Yang L; Zheng LY; Pan YY; Cao ZF; Zhang ZQ; Zhou QS; Yang B; Cao C
    BMC Cancer; 2014 May; 14():373. PubMed ID: 24886166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suberoylanilide hydroxamic acid represses glioma stem-like cells.
    Hsu CC; Chang WC; Hsu TI; Liu JJ; Yeh SH; Wang JY; Liou JP; Ko CY; Chang KY; Chuang JY
    J Biomed Sci; 2016 Nov; 23(1):81. PubMed ID: 27863490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
    Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Purified vitexin compound 1 induces apoptosis through activation of FOXO3a in hepatocellular carcinoma.
    Wang JG; Zheng XX; Zeng GY; Zhou YJ; Yuan H
    Oncol Rep; 2014 Jan; 31(1):488-96. PubMed ID: 24247909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
    Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
    PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells.
    Seo SK; Jin HO; Lee HC; Woo SH; Kim ES; Yoo DH; Lee SJ; An S; Rhee CH; Hong SI; Choe TB; Park IC
    Mol Pharmacol; 2008 Mar; 73(3):1005-12. PubMed ID: 18156316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
    McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
    Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth-suppressive effect of suberoylanilide hydroxamic acid (SAHA) on human oral cancer cells.
    Jang B; Shin JA; Kim YS; Kim JY; Yi HK; Park IS; Cho NP; Cho SD
    Cell Oncol (Dordr); 2016 Feb; 39(1):79-87. PubMed ID: 26582320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
    Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM
    Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.